Skip to main content

POPULATION GENETICS AND EVOLUTION OF MICROBIAL PATHOGENS INTEGRATED WITH MOLECULAR EPIDEMIOLOGY

RYC-2015-18213

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Incorporación
Call Ramón y Cajal
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Investigación, Desarrollo e Innovación
Beneficiary centre UNIVERSITAT DE VALÈNCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation

  • Ginex, Tiziana
  • Marco-Marín, Clara
  • Wieczor, Milosz
  • Mata, Carlos P.
  • Krieger, James
  • Ruiz-Rodríguez, Paula
  • López-Redondo, Marisa
  • Francés-Gómez, Clara
  • Melero, Roberto
  • Sorzano, Carlos Óscar S.
  • Martínez, Marta
  • Gougeard, Nadine
  • Forcada-Nadal, Alicia
  • Zamora-Caballero, Sara
  • Gozalbo-Rovira, Roberto
  • Sanz-Frasquet, Carla
  • Arranz, Rocío
  • Bravo, Jerónimo
  • Rubio, Vicente
  • Marina, Alberto
  • The IBV-Covid19-Pipeline Consortium
  • Geller, Ron
  • Comas, Iñaki
  • Gil, Carmen
  • Coscollá, Mireia
  • Orozco, Modesto
  • Llácer, José Luis
  • Carazo, José M.
The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has since reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness., In this research work, PRR and TG were supported by salaries from the European Commission–NextGenerationEU through the CSIC Global Health Platform established by EU Council Regulation 2020/2094. The authors would like to acknowledge economic support from: (a) the Spanish Ministry of Science and Innovation through grants: SEV-2017-0712 funded by MCIN/AEI/10.13039/501100011033 (CPM, JK, RM, COSS, MM, RA, JMC); 116880GB-I00 (JLL) and 120322RB-C21 (VR) funded within PID 2020; PID2019-104757RB-I00 funded by MCIN/AEI/10.13039/501100011033/ and “ERDF A way of making Europe”, by the “European Union” (JMC, COSS, RM, MM, CPM) and 104477RB-100 (IC) funded within PID 2019; RYC-2015-18213 (salary of MC) and RYC-2015-17517 (salary of RG) funded by the Ramon y Cajal fellowship program; RTI2018-094399-A-I00 (JMC, COSS, RM, CPM, MC) funded within the Retos Investigación program; the CRIOMECORR project funded as ESFRI-2019-01-CSIC-16; (b) the Horizon 2020 program through Marie Skłodowska-Curie Individual Fellowships EnLaCES (Proposal 101024130, salary of JK) and EPIDNA (Grant ID: 894498, salary of MW); (c) the European Research Council (ERC) through grants: ERC-2018-SyG-810057 HighResCells funded within the EXCELLENT SCIENCE program (JMC, MM, COSS, salary of RM), Grant 871037 iNEXT DISCOVERY (JMC, MM, COSS) and grant CoG-101001038 funded within the Consolidator Grants program (IC); (d) Generalitat Valenciana through grants: SEJI/2019/011 (MC) and SEJI/2019/030 (JLL); (e) Comunidad de Madrid through grant: S2017/BMD-3817 (JMC); (f) Santander Bank through grant: CSIC-COVID19-082 (AM, VR, JB, JLL, RG) funded through the Fondo Supera Covid-19; (g) Instituto de Salud Carlos III through grants: COV20/00437 (AM, VR, JB, JLL) and COV20/00140 (IC), both funded through the Fondos Covid-19 initiative; (h) Spanish National Research Council through grant: 202080E110 funded within the PTI Salud Global initiative (AM, VR, JB, JLL, RG)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype

  • Renau-Mínguez, Chantal
  • Herrero-Abadía, Paula
  • Ruiz-Rodríguez, Paula
  • Sentandreu, Vicente
  • Torrents, Eduard
  • Chiner-Oms, Álvaro
  • Torres-Puente, Manuela
  • Comas, Iñaki
  • Julián, Esther
  • Coscollá, Mireia
Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. Mycobacterium brumae is not pathogenic and it's in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. Mycobacterium brumae genome is composed of a circular chromosome with a high GC content of 69.2% and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. Mycobacterium brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence-related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although the immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae genome is considerably lower than those antigens present in M. bovis BCG genome. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential., This research was funded by the Spanish Ministry of Science, Innovation, and Universities (MICIN) and co-funded by the FEDER Funds (RTI2018-098777-B-I00, RTI2018-094399-A-I00, PID2021-125801OB-I00, PID2021-122331OB-I00, and PID2021-123443OB-I00), the AGAUR-Generalitat of Catalunya (2017SGR229 and 2017SGR-1079), Ramón y Cajal fellowship (RYC-2015-18213 MICIN), FPI fellowship (PRE-2019-088141 MICIN), Generalitat Valenciana (SEJI/2019/011), MycoNET (RED2018-102677-T), and the European Commission—NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Program (PTI+ Salud Global)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype

  • Renau-Mínguez, Chantal
  • Herrero Abadía, Paula|||0000-0001-9747-1818
  • Ruiz-Rodriguez, Paula
  • Sentandreu, Vicente
  • Torrents, Eduard|||0000-0002-3010-1609
  • Chiner-Oms, Álvaro|||0000-0002-0463-0101
  • Torres-Puente, Manuela|||0000-0002-8352-180X
  • Comas, I.|||0000-0001-5504-9408
  • Julián, Esther|||0000-0002-6558-3978
  • Coscolla, Mireia
Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. Mycobacterium brumae is not pathogenic and it's in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384 T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. Mycobacterium brumae genome is composed of a circular chromosome with a high GC content of 69.2% and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. Mycobacterium brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence-related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although the immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae genome is considerably lower than those antigens present in M. bovis BCG genome. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential.